Updated: Seaport and Hemab file for IPOs, as Kailera pricesnews2026-04-13T01:10:39+00:00April 13th, 2026|Endpoints News|
GSK plans five Phase 3 studies for gynecological cancer ADC from Hansohnews2026-04-12T14:10:11+00:00April 12th, 2026|Endpoints News|
More pharma dealmaking; FDA’s proposed budget; Takeda ends partnership; and morenews2026-04-11T10:00:58+00:00April 11th, 2026|Endpoints News|
Plan for remade ACIP panel adds focus on vaccine safety, matching Kennedy’s pushnews2026-04-10T19:00:33+00:00April 10th, 2026|Endpoints News|
Bayer pharma executive predicts US-Europe price spreads will narrownews2026-04-10T18:28:15+00:00April 10th, 2026|Endpoints News|
FDA rejects Replimune cancer therapy, saying company didn’t resolve trial doubtsnews2026-04-10T16:16:03+00:00April 10th, 2026|Endpoints News|
China biotech’s CRISPR therapy suggests US drugmakers will face competitionnews2026-04-10T15:54:15+00:00April 10th, 2026|Endpoints News|
Vivatides gets $54M; Wegovy drops cold chain in EU; Gilead takes Kymera optionnews2026-04-10T15:13:51+00:00April 10th, 2026|Endpoints News|
Biotech VCs ramp up checks on new bets after years of focusing on existing portfoliosnews2026-04-10T14:27:52+00:00April 10th, 2026|Endpoints News|
Novo’s double departures: As GLP-1 luminary retires, an obesity leader goes to Boehringer Ingelheimnews2026-04-10T11:00:11+00:00April 10th, 2026|Endpoints News|
